Related Experiment Video

Updated: Apr 19, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

354

p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma

Zhen Li1, Yin Sun2, Xufeng Chen1

  • 1Department of Pathology and Urology, Jonsson Comprehensive Cancer Center and Broad Center of Regenerative Medicine and Stem Cell Research, UCLA David Geffen School of Medicine, Los Angeles, California.

Molecular Cancer Research : MCR
|December 17, 2014
PubMed
Abstract

Insights

Prostate small cell neuroendocrine carcinoma (SCNC) is driven by p53 mutations. These mutations increase Aurora Kinase A (AURKA) levels, fueling aggressive cancer growth and offering potential therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Prostatic small cell neuroendocrine carcinoma (SCNC) is an aggressive prostate cancer subtype.
  • SCNC is androgen receptor (AR)-negative and resistant to hormonal therapy.
  • The molecular drivers of SCNC are not fully understood.

Purpose of the Study:

  • To investigate the molecular relationship between p53 mutation and Aurora Kinase A (AURKA) expression in SCNC.
  • To elucidate the intracellular pathway linking p53 inactivation to AURKA upregulation.
  • To identify potential therapeutic targets in SCNC pathogenesis.

Main Methods:

  • Analysis of the p53, IL8-CXCR2-p53 pathway in prostate neuroendocrine cells.
  • Investigation of miR-25 and FBXW7 E3 ubiquitin ligase expression.
  • Assessment of AURKA levels in relation to p53 mutation status.

Main Results:

  • p53 mutation inactivates the IL8-CXCR2-p53 pathway, promoting proliferation.
  • p53 mutation increases miR-25 expression and downregulates FBXW7.
  • This leads to elevated AURKA levels, crucial for SCNC proliferation and aggressiveness.

Conclusions:

  • Prostatic SCNC pathogenesis involves a p53 and AURKA signaling mechanism.
  • Both p53 and AURKA represent potentially targetable pathways for SCNC treatment.
  • Understanding this pathway is critical for managing aggressive prostate cancer.

More Related Videos

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

3.6K
Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH07:54

Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH

Published on: August 19, 2014

17.7K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
39.2K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.4K